Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s share price rose 5.8% during mid-day trading on Wednesday . The stock traded as high as $27.45 and last traded at $27.01, with a volume of 1,576,189 shares traded. The stock had previously closed at $25.52.

A number of brokerages have recently weighed in on SRPT. Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 3rd. William Blair lowered Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 21st. Vetr upgraded Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price objective on the stock in a research report on Thursday, June 2nd. Needham & Company LLC lifted their price objective on Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, July 22nd. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. Sarepta Therapeutics has a consensus rating of “Hold” and a consensus target price of $25.28.

The firm’s market capitalization is $1.24 billion. The company has a 50 day moving average price of $20.86 and a 200-day moving average price of $17.61.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the previous year, the company earned ($0.87) earnings per share. On average, equities research analysts expect that Sarepta Therapeutics Inc. will post ($5.12) earnings per share for the current year.

Several hedge funds and institutional investors have added to or reduced their stakes in SRPT. Creative Planning boosted its position in shares of Sarepta Therapeutics by 95.7% in the fourth quarter. Creative Planning now owns 52,950 shares of the company’s stock valued at $2,043,000 after buying an additional 25,900 shares during the period. Nationwide Fund Advisors boosted its position in shares of Sarepta Therapeutics by 9.2% in the fourth quarter. Nationwide Fund Advisors now owns 29,223 shares of the company’s stock valued at $1,127,000 after buying an additional 2,471 shares during the period. Swiss National Bank boosted its position in shares of Sarepta Therapeutics by 5.8% in the fourth quarter. Swiss National Bank now owns 61,700 shares of the company’s stock valued at $2,380,000 after buying an additional 3,400 shares during the period. Rhumbline Advisers boosted its position in shares of Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock valued at $1,841,000 after buying an additional 6,615 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of Sarepta Therapeutics by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock valued at $1,725,000 after buying an additional 5,300 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.